Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Here's Why Investors Should Buy Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on ongoing business recovery.
Alcon (ALC) Unveils Expansive Vision Care Products at SECO 2023
by Zacks Equity Research
Alcon (ALC) showcases its reusable toric lens and dry eye/ocular health offerings at the SECO International Meeting 2023 in Atlanta.
Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access
by Zacks Equity Research
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
Zimmer Biomet (ZBH) Gains From Market Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) witnesses continued traction across hip products, including the G7 revision system and Avenir Complete primary hip.
Haemonetics (HAE) Autotransfusion System Gets 510(k) Clearance
by Zacks Equity Research
The latest development is expected to upgrade Haemonetics' (HAE) Cell Salvage platform and broaden the company's scope in the growing autotransfusion space.
Neogen's (NEOG) New Launches Aid, Margin Pressure Stays
by Zacks Equity Research
Neogen (NEOG) continues to see rising revenues from the Food Safety business.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on the continued strength of GYN Surgical and Breast Health businesses.
Hologic's (HOLX) Strategic Buyouts Aid, Surgical Arm Grows
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical results underscore a more diverse surgical business with more growth drivers than in the past.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on the growing market adoption of the iTero Element 5D Plus imaging system.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strong global performance.
Medtronic's (MDT) MiniMed 780G System Shows Favorable Results
by Zacks Equity Research
Medtronic's (MDT) MiniMed 780G system was designed to forecast real-life requirements where carbohydrate counts aren't always exact and meal doses are often missed.
Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Agios (AGIO) reports mixed fourth-quarter results as earnings beat estimates and revenues miss the same.
Bull of the Day: Haemonetics (HAE)
by Kevin Cook
Leader in blood management for hospitals see estimates and price targets rise after strong quarter
New Strong Buy Stocks for February 10th
by Zacks Equity Research
SNEX, DTEGY, CLVT, HAE and ARCC have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2022.
Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.
3 Medical Products Stocks Navigating Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.
Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 7.59% and 4.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) to Post Q4 Earnings: What You Should Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.
Can Lower Managed Care Profits Hurt Centene (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and memberships.
STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.73% and 3.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?